[1] World Health Organization. Weekly epidemiological update on COVID-19 - 30 November 2021. 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2021. [2022-5-15].https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2021
[2] GitHub. BA.2 sub-lineage with S:I1221T dominant in Hong Kong #430. 2022. https://github.com/cov-lineages/pango-designation/issues/430. [2022-5-15].https://github.com/cov-lineages/pango-designation/issues/430
[3] GitHub. Proposal to split B.1.1.529 to incorporate a newly characterised sibling lineage #361. 2021. https://github.com/cov-lineages/pango-designation/issues/361. [2022-5-15].https://github.com/cov-lineages/pango-designation/issues/361
[4] Panzera Y, Ramos N, Frabasile S, Calleros L, Marandino A, Tomás G, et al. A deletion in SARS‐CoV‐2 ORF7 identified in COVID-19 outbreak in Uruguay. Transbound Emerg Dis 2021;68(6):3075 − 82. http://dx.doi.org/10.1111/tbed.14002CrossRef
[5] Zhou ZL, Huang CL, Zhou ZC, Huang ZX, Su LL, Kang SS, et al. Structural insight reveals SARS-CoV-2 Orf7a as an immunomodulating factor for human CD14+monocytes. iScience 2021;24(3):102187. http://dx.doi.org/10.1016/j.isci.2021.102187CrossRef
[6] Young BE, Fong SW, Chan YH, Mak TM, Ang LW, Anderson DE, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet 2020;396(10251):603 − 11. http://dx.doi.org/10.1016/S0140-6736(20)31757-8CrossRef